Compare KRYS & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | CRL |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 7.5B |
| IPO Year | 2017 | 1999 |
| Metric | KRYS | CRL |
|---|---|---|
| Price | $262.33 | $170.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $297.60 | $200.09 |
| AVG Volume (30 Days) | 217.1K | ★ 761.0K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 6.84 | N/A |
| Revenue | $389,130,000.00 | ★ $1,857,601,000.00 |
| Revenue This Year | $39.88 | $0.99 |
| Revenue Next Year | $34.38 | $3.26 |
| P/E Ratio | $38.23 | ★ N/A |
| Revenue Growth | ★ 33.94 | 10.48 |
| 52 Week Low | $123.03 | $91.86 |
| 52 Week High | $298.30 | $228.88 |
| Indicator | KRYS | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 51.86 |
| Support Level | $251.93 | $166.86 |
| Resistance Level | $293.60 | $182.76 |
| Average True Range (ATR) | 9.28 | 7.16 |
| MACD | 2.05 | 2.30 |
| Stochastic Oscillator | 90.05 | 66.53 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.